A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.
GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.
A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.